Published November 28,2023
Subscribe
Japan on Tuesday introduced its first home COVID-19 vaccine towards the Omicron XBB.1.5 coronavirus subvariant.
A Health Ministry panel mentioned that the vaccine developed by pharmaceutical agency Daiichi Sankyo is authorized for sensible use, Tokyo-based NHK news company reported.
Experts on the panel mentioned “they confirmed the vaccine’s effectiveness, and that they have no serious concerns over its safety.”
The vaccine will probably be distributed nationwide in December upon receiving ministry approval.
The ministry authorized Daiichi Sankyo’s plan to supply and promote 1.4 million doses of the XBB.1.5-adapted vaccine, resulting in the acquisition settlement.
Of about 34 million instances of COVID-19 since early 2020, Japan suffered about 75,000 deaths, based on Worldometer figures.
Source: www.anews.com.tr
